» Articles » PMID: 20838951

Novel Aspect of Ketone Action: β-hydroxybutyrate Increases Brain Synthesis of Kynurenic Acid in Vitro

Overview
Journal Neurotox Res
Publisher Springer
Specialty Neurology
Date 2010 Sep 15
PMID 20838951
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Ketone bodies formed during ketogenic diet or non-treated diabetes mellitus may exert neuroprotective and antiepileptic effects. Here, we assessed the influence of ketone body, β-hydroxybutyrate (BHB) on the brain synthesis of kynurenic acid (KYNA), an endogenous antagonist of glutamatergic and α7-nicotinic receptors. In brain cortical slices and in primary glial cultures, BHB enhanced KYNA production. KT 5270, an inhibitor of protein kinase A, has prevented this action. At hypoglycemia, under pH 7.0 and 7.4, profound (15 mM BHB), but not mild (3 mM) ketosis increased synthesis of KYNA. In paradigm resembling diabetic ketoacidosis in vitro (30 mM glucose, pH 7.0), neither mild nor profound ketosis influenced the production of KYNA. At pH 7.4 and in 30 mM glucose though, both mild and severe ketonemia evoked an increase of KYNA production. The activity of KYNA biosynthetic enzymes, KAT I and KAT II, in cortical homogenate was not altered by BHB (0.05-10.0 mM). However, in cultured glial cells exposed to BHB (10 mM), the activity of KATs increased. This effect was reversed by the co-incubation of cells with KT 5270. Presented data reveal a novel mechanism of action of BHB. Increased synthesis of KYNA in the presence of BHB is most probably mediated by protein kinase A-dependent stimulation of KATs expression/activity leading to an increase of KYNA formation. Ensuing attenuation of the excessive excitatory glutamate-mediated neurotransmission may, at least in part, explain the neuroprotective actions of BHB.

Citing Articles

Memantine and the Kynurenine Pathway in the Brain: Selective Targeting of Kynurenic Acid in the Rat Cerebral Cortex.

Kloc R, Urbanska E Cells. 2024; 13(17.

PMID: 39272996 PMC: 11394628. DOI: 10.3390/cells13171424.


The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects.

Alves L, Moore J, Kell D Int J Mol Sci. 2024; 25(16).

PMID: 39201768 PMC: 11354673. DOI: 10.3390/ijms25169082.


The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy.

Stone T, Darlington L, Badawy A, Williams R Int J Mol Sci. 2024; 25(16).

PMID: 39201726 PMC: 11354734. DOI: 10.3390/ijms25169040.


Exploring the effect of prolonged fasting on kynurenine pathway metabolites and stress markers in healthy male individuals.

Louvrou V, Solianik R, Brazaitis M, Erhardt S Eur J Clin Nutr. 2024; 78(8):677-683.

PMID: 38789718 PMC: 11300305. DOI: 10.1038/s41430-024-01451-7.


Kynurenine Pathway in Diabetes Mellitus-Novel Pharmacological Target?.

Koziel K, Urbanska E Cells. 2023; 12(3).

PMID: 36766803 PMC: 9913876. DOI: 10.3390/cells12030460.


References
1.
Hartman A, Gasior M, Vining E, Rogawski M . The neuropharmacology of the ketogenic diet. Pediatr Neurol. 2007; 36(5):281-92. PMC: 1940242. DOI: 10.1016/j.pediatrneurol.2007.02.008. View

2.
Noh H, Hah Y, Nilufar R, Han J, Bong J, Kang S . Acetoacetate protects neuronal cells from oxidative glutamate toxicity. J Neurosci Res. 2006; 83(4):702-9. DOI: 10.1002/jnr.20736. View

3.
Suzuki Y, Takahashi H, Fukuda M, Hino H, Kobayashi K, Tanaka J . Beta-hydroxybutyrate alters GABA-transaminase activity in cultured astrocytes. Brain Res. 2009; 1268:17-23. DOI: 10.1016/j.brainres.2009.02.074. View

4.
Rho J, Anderson G, Donevan S, White H . Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia. 2002; 43(4):358-61. DOI: 10.1046/j.1528-1157.2002.47901.x. View

5.
Fukao T, Lopaschuk G, Mitchell G . Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids. 2004; 70(3):243-51. DOI: 10.1016/j.plefa.2003.11.001. View